Given the availability of new agents to treat FD, and a growing body of evidence that enzyme-focused treatment might mitigate progression, what is the rationale for suspecting and confirming the diagnosis of FD?

Given the availability of new agents to treat FD, and a growing body of evidence that enzyme-focused treatment might mitigate progression, what is the rationale for suspecting and confirming the diagnosis of FD?

Given the availability of new agents to treat FD, and a growing body of evidence that enzyme-focused treatment might mitigate progression, what is the rationale for suspecting and confirming the diagnosis of FD? What do U.S. and European Guidelines recommend as far as timing of intervention?


Created by

CMEducation Resources IQ&A Fabry Disease Diagnostic Intelligence Zone

Presenter

Robert Hopkin

Robert Hopkin

Associate Professor of Clinical Pediatrics
Cincinnati Children's Hospital Medical Center
Co-Director, 22Q-VCFS Center
University of Cincinnati College of Medicine
Cincinnati, OH